More about

Adalimumab

News
May 15, 2023
2 min read
Save

Patients with hidradenitis suppurativa benefit when treatment combines adalimumab, surgery

Patients with hidradenitis suppurativa benefit when treatment combines adalimumab, surgery

Adalimumab accompanied by surgery significantly out-performed adalimumab monotherapy in the treatment of patients with moderate to severe hidradenitis suppurativa, according to a study.

News
April 20, 2023
2 min read
Save

Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s

Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s

Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.

News
April 17, 2023
1 min read
Save

FDA denies Alvotech’s application for Humira biosimilar candidate

FDA denies Alvotech’s application for Humira biosimilar candidate

The FDA has denied a biologics license application to Alvotech for AVT02, a high-concentration adalimumab biosimilar candidate, according to a press release from Teva Pharmaceutical Industries.

News
April 05, 2023
2 min read
Save

Benefits outweigh risks when switching biologics for rheumatoid arthritis

Benefits outweigh risks when switching biologics for rheumatoid arthritis

Patients with rheumatoid arthritis who achieve only a partial response with adalimumab demonstrate a low risk for worsened symptoms and a high likelihood of meaningful improvement when switching to sarilumab, according to data.

News
March 27, 2023
2 min read
Save

FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz

FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

News
March 08, 2023
2 min read
Save

Longer adalimumab dose intervals improve infection risk, worsen remission rates in Crohn’s

Longer adalimumab dose intervals improve infection risk, worsen remission rates in Crohn’s

Increasing adalimumab dose intervals reduced infection-related adverse events and costs in patients with Crohn’s disease, but also resulted in lower remission rates, researchers reported in The Lancet Gastroenterology & Hepatology.

News
March 04, 2023
1 min read
Save

More than 90% of GIs are ‘somewhat comfortable’ prescribing adalimumab biosimilars

More than 90% of GIs are ‘somewhat comfortable’ prescribing adalimumab biosimilars

Most gastroenterologists reported higher familiarity with adalimumab biosimilars and reported greater comfort levels in prescribing biosimilars than dermatologists or rheumatologists, according to a recent survey.

News
March 02, 2023
2 min read
Save

Few rheumatologists say economic benefits of biosimilars sufficient to warrant switching

Few rheumatologists say economic benefits of biosimilars sufficient to warrant switching

Although most rheumatologists report they are comfortable with the idea of prescribing biosimilars, only approximately 18% think the economic benefits warrant switching their patients to one, according to a Cardinal Health survey.

News
January 21, 2023
3 min read
Save

‘Proactive education’ critical to preparing patients for likely biosimilar switch

‘Proactive education’ critical to preparing patients for likely biosimilar switch

DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can help reduce anxiety and bias if/when their insurance opts to switch, according to a presenter at the Crohn’s and Colitis Congress.

News
January 17, 2023
2 min read
Save

Adding TNF inhibitor, triple therapy to RA treatment improves vascular inflammation

Adding TNF inhibitor, triple therapy to RA treatment improves vascular inflammation

In patients with active rheumatoid arthritis despite methotrexate use, adding either a TNF inhibitor or triple therapy with sulfasalazine and hydroxychloroquine improves vascular inflammation, according to data.

View more